Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
Focal Dystonia and Botulinum Toxin: Our Experience with IncobotulinumtoxinA
by
Tacconi, Leonello
, Manganot, Paolo
, Tomasell, Marinella
, Mazzon, Giulia
in
Botulinum toxin
/ Dystonia
/ Immune response
/ Signs and symptoms
2019
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Focal Dystonia and Botulinum Toxin: Our Experience with IncobotulinumtoxinA
by
Tacconi, Leonello
, Manganot, Paolo
, Tomasell, Marinella
, Mazzon, Giulia
in
Botulinum toxin
/ Dystonia
/ Immune response
/ Signs and symptoms
2019
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Focal Dystonia and Botulinum Toxin: Our Experience with IncobotulinumtoxinA
Journal Article
Focal Dystonia and Botulinum Toxin: Our Experience with IncobotulinumtoxinA
2019
Request Book From Autostore
and Choose the Collection Method
Overview
Botulinum toxin type A (BTX-A) represent the gold standard therapy for focal dystonia and related hyperkinetic movement disorders. The main advantages of this method are low rate of complications, reversibility and efficacy in reducing spastic hypertonia or abnormal movements. The treatment is safe but it needs to be repeated periodically and some patients do not obtain effective control of the symptoms due to the onset of secondary immune resistance. For this reason we have selected 45 cases already in treatment with botulinum toxin that have been switched to incobotulinumtoxinA. At a median follow up of 8 months the greatest part of the patients, twenty-six (57.7%) remained clinically unchanged; fourteen (31.1%) had a significant clinical improvement and five (11.1%) worsened. We did not observe any general or injection site complications
Publisher
NeuroQuantology
Subject
MBRLCatalogueRelatedBooks
Related Items
Related Items
We currently cannot retrieve any items related to this title. Kindly check back at a later time.
This website uses cookies to ensure you get the best experience on our website.